Literature DB >> 3130390

Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.

A L Barry1, R N Jones.   

Abstract

The accuracy of disk susceptibility tests with ampicillin and ampicillin-sulbactam was not improved when the amount of ampicillin was increased from 10 to 20 or 30 micrograms per disk. For testing members of the family Enterobacteriaceae, ampicillin disk tests correlated better with broth microdilution tests when the zone size standards were altered from greater than or equal to 14 greater than or equal to 17 mm for susceptible and from less than or equal to 11 to less than or equal to 13 mm for resistant. The same zone size breakpoints apply to tests with ampicillin-sulbactam disks (10/10 micrograms). When Staphylococcus, Branhamella, and Haemophilus species are tested against ampicillin, interpretive breakpoints are those separating beta-lactamase-producing strains from nonproducing strains. However, when ampicillin-sulbactam is tested, beta-lactamase enzymes are efficiently inhibited by the sulbactam component, and thus zone size standards for ampicillin do not apply: zone size standards for the Enterobacteriaceae can be used for testing the combination against Staphylococcus, Branhamella, and Haemophilus species. For Streptococcus, Enterococcus, and Listeria species, only ampicillin disks need be tested, since ampicillin-sulbactam disks give essentially identical results.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3130390      PMCID: PMC266439          DOI: 10.1128/jcm.26.4.750-754.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Antibiotic susceptibility of clinical isolates of Listeria monocytogenes.

Authors:  G L Wiggins; W L Albritton; J C Feeley
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

2.  Laboratory determination of antibiotic susceptibility to ampicillin and cephalothin.

Authors:  J C Sherris; A L Rashad; G A Lighthart
Journal:  Ann N Y Acad Sci       Date:  1967-09-27       Impact factor: 5.691

3.  Disk diffusion susceptibility of Branhamella catarrhalis and relationship of beta-lactam zone size to beta-lactamase production.

Authors:  I Luman; R W Wilson; R J Wallace; D R Nash
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

4.  Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.

Authors:  R M Brown; R Wise; J M Andrews; J Hancox
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

5.  Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

6.  Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

Review 7.  Pharmacokinetics of sulbactam/ampicillin in humans: a review.

Authors:  G Foulds
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

8.  A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor.

Authors:  N Aswapokee; H C Neu
Journal:  J Antibiot (Tokyo)       Date:  1978-12       Impact factor: 2.649

9.  CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.

Authors:  J A Retsema; A R English; A E Girard
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

10.  Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus.

Authors:  R G Washburn; D T Durack
Journal:  J Infect Dis       Date:  1981-09       Impact factor: 5.226

View more
  6 in total

1.  Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

2.  Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 3.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

4.  Ampicillin-sulbactam susceptibility testing criteria.

Authors:  A Barry; M Pfaller; P Fuchs; E Gerlach; D Hardy; J McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

5.  In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

6.  In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.

Authors:  F A Sarubbi; A Verghese; C Caggiano; S Holtsclaw-Berk; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.